Nov 18, 2009
By:George Koroneos, Online Content & News Editor
Nearly 70 pharma execs, new media mavens, and even Joe Q. Public packed last week's FDA social media hearings to plead for some form of guidance on how to handle Tweets, blog comments, and off label discussions online.
 |
Nov 4, 2009
By:George Koroneos, Online Content & News Editor
Johnson & Johnson announced a massive restructuring plan on Tuesday in an effort to save $1.4 billion to $1.7 billion by 2011. The human cost: 7 percent of its workforce.
|
Oct 28, 2009
By:George Koroneos, Online Content & News Editor
The US oversight arm scripted a hefty report complaining that FDA is not moving fast enough when it comes to screening clinical trials data for drugs green lit through its expedited approval program.
|
Oct 21, 2009
By:George Koroneos, Online Content & News Editor
The third quarter reports are in, and Pfizer's profits are up but sales are down. The company is compensating for looming patent expirations with layoffs and restructuring; is it enough to boost sales?
|
Oct 14, 2009
By:George Koroneos, Online Content & News Editor
GSK is being ordered to pay $2.5 million in restitution to a Pennsylvania family. The firm was accused of not doing enough to warn consumers that taking the antidepressant Paxil, while pregnant, could lead to birth defects.
|
Oct 14, 2009
By:George Koroneos, Online Content & News Editor
Sandoz Shire Pharmaceuticals announced that it would allow Sandoz to market a generic version of its blockbuster ADHD med Adderall XR if it can clear FDA. But that's a big if.
|
Oct 8, 2009
By:George Koroneos, Online Content & News Editor
Sure, industry growth is at "historically low levels," but at least pharma is still growing. The industry's market value should surpass $825 billion in 2010, and forecasted growth was bumped up one percentage point from original estimates.
|
Oct 7, 2009
By:George Koroneos, Online Content & News Editor
Pulling off an incredibly fast turnaround, the pharma industry has released a vaccine for the H1N1 virus, bolstering its bottom line with a second flu vaccine and potentially helping millions of people. So why is there such an uproar over whether it's safe?
|
| 
PharmExec Blog
Follow Us
RSS
Bookstore
What's the best managed pharma? Professor Bill Trombetta of Saint Joseph's University attempts to answer the question in Pharm Exec's Industry Audit.
Applying E-Commerce to Support Discovery and Development of Medicines: Key Lessons and Learnings Tuesday, December 15 @ 11:00 a.m. ET
The most respected annual ranking of top 50 pharmaceutical companies by prescription drug sales... Who's in, who's back, and who's out?